AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

DIMERIX LTD

0.595

-0.015-2.46%

Volume:3.83M

Turnover:2.34M

Market Cap:332.86M

PE:-13.46

High:0.635

Open:0.605

Low:0.595

Close:0.610

Loading ...

Overview Company News Filings

Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today

BRIEF-Dimerix Receives Upfront Payment Of $30 Million From Amicus Therapeutics

Dimerix Ltd - Received Upfront Payment of US$30 Mln From Amicus Therapeutics

THOMSON REUTERS

Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today

BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug

Guess which ASX All Ords stock is rocketing 58% on big US news

Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%

MT Newswires Live

BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Dimerix Ltd - Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for Dmx-200 in United States

THOMSON REUTERS

Dimerix Ltd - Dimerix to Receive US$30 Mln Upfront Payment

THOMSON REUTERS

BRIEF-Dimerix Seeks Trading Halt

Dimerix - Seeks Trading Halt Pending Announcement on Licensing Agreement

THOMSON REUTERS

Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal

MT Newswires Live

BRIEF-Dimerix Receives Initial Upfront Payment From FUSO

Dimerix posts modest gain as first Japanese payment for DMX-200 lands

The Market Herald

Dimerix Ltd - Dimerix Receives Initial Upfront Payment From Fuso

THOMSON REUTERS

BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 Mln

Dimerix Ltd - Loss for Half-Year Attributable a$12.9 Mln

THOMSON REUTERS

Lowering Dimerix's Phase 3 Trial Hurdles to Boost Kidney Failure Treatment Drug Appeal, Euroz Hartleys Says.

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DXB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.595,"timestamp":1747116720000,"preClose":0.61,"halted":0,"volume":3832061,"delay":0,"nameEN":"DIMERIX LTD","floatShares":438634329,"shares":559426763,"eps":-0.044195,"marketStatus":"Closed","change":-0.015,"latestTime":"05-13 16:12:00 AEST","open":0.605,"high":0.635,"low":0.595,"amount":2342231,"amplitude":0.065574,"askPrice":0.595,"askSize":7371,"bidPrice":0.59,"bidSize":410219,"shortable":3,"etf":0,"ttmEps":-0.044195,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747180800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.61,"openAndCloseTimeList":[[1747094400000,1747116000000]],"volumeRatio":0.719151,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":438634329,"roa":"-79.26%","roe":"-524.68%","lyrEps":-0.0377,"volumeRatio":0.719151,"shares":559426763,"dividePrice":0,"high":0.635,"amplitude":0.065574,"preClose":0.61,"low":0.595,"week52Low":0.3,"pbRate":"46.44","psRate":"451.11","week52High":0.785,"institutionHeld":0,"latestPrice":0.595,"committee":0.964697,"eps":-0.044195,"divideRate":0,"volume":3832061,"delay":0,"ttmEps":-0.044195,"open":0.605,"prevYearClose":0.34,"prevWeekClose":0.66,"prevMonthClose":0.48,"prevQuarterClose":0.415,"fiveDayClose":0.695,"twentyDayClose":0.375,"sixtyDayClose":0.505},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533517776","title":"Why Dimerix, Evolution Mining, Inghams, and NextDC shares are charging higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2533517776","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533517776?lang=en_us&edition=fundamental","pubTime":"2025-05-06 10:36","pubTimestamp":1746499006,"startTime":"0","endTime":"0","summary":"In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is no course to record a small decline. At the time of writing, the benchmark index is down almost 0.2% to 8,144.3 points. Four ASX shares that are","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/06/why-dimerix-evolution-mining-inghams-and-nextdc-shares-are-charging-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["DXB.AU","EPM","BK7104","NXT.AU","BK7043","ING.AU","BK7508","BK7505","BK7141","BK7501","BK7506","XJO.AU","EVN.AU","BK7503","BK7067","BK4213"],"gpt_icon":0},{"id":"2533594171","title":"BRIEF-Dimerix Receives Upfront Payment Of $30 Million From Amicus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2533594171","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533594171?lang=en_us&edition=fundamental","pubTime":"2025-05-06 09:32","pubTimestamp":1746495143,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Receives Upfront Payment Of $30 Million From Amicus TherapeuticsMay 6 (Reuters) - Dimerix Ltd DXB.AX:RECEIVED UPFRONT PAYMENT OF US$30 MILLION FROM AMICUS THERAPEUTICSFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250506:nFWN3RD226:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","DXB.AU","BK7508","BK7501"],"gpt_icon":0},{"id":"2533623365","title":"Dimerix Ltd -  Received Upfront Payment of US$30 Mln From Amicus Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2533623365","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533623365?lang=en_us&edition=fundamental","pubTime":"2025-05-06 06:27","pubTimestamp":1746484057,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250505:nFWN3RD226:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2532389310","title":"Why Boss Energy, Capstone, Dimerix, and Platinum shares are storming higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2532389310","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532389310?lang=en_us&edition=fundamental","pubTime":"2025-05-02 11:33","pubTimestamp":1746156793,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.9% to 8,218.5 points. Four ASX shares that are rising more than mos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/02/why-boss-energy-capstone-dimerix-and-platinum-shares-are-storming-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4139","DXB.AU","LU2065169927.USD","BK7062","BK7508","BK7067","LU2065170008.USD","LU2065171311.SGD","XJO.AU","CSC.AU","LU2065171402.SGD","BK7501","PTM.AU","FOLD","BK7083","BOE.AU","BK7110"],"gpt_icon":0},{"id":"2532049548","title":"BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2532049548","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532049548?lang=en_us&edition=fundamental","pubTime":"2025-05-01 12:23","pubTimestamp":1746073390,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix hits nearly 5-year high on US license for its drug** Dimerix DXB.AX surges as much as 58.33% to A$0.760, highest since September 9, 2020** Stock marks biggest intraday pct gain since October 5, 2023** Biotech firm announces exclusive license agreement with Amicus Therapeutics FOLD.O to commercialise its Phase 3 drug candidate, DMX-200, in the U.S.** Says DMX-200 currently being developed to treat focal segmental glomerulosclerosis kidney disease** Stock sees busiest session since October 6, 2023, with more than 31 mln shares traded - 18.3x the 30-day avg** Last up 50%, DXB more than doubles YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nL4N3R909Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","LU2065171402.SGD","LU2065169927.USD","BK7067","BK7508","BK4139","LU2065171311.SGD","FOLD","LU2065170008.USD","BK7501"],"gpt_icon":0},{"id":"2532108840","title":"Guess which ASX All Ords stock is rocketing 58% on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2532108840","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532108840?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:13","pubTimestamp":1746062011,"startTime":"0","endTime":"0","summary":"The share market may be struggling to get into gear on Thursday but that isn't stopping one ASX All Ords stock from racing higher. In morning trade, its shares are up a massive 58% to 76 cents thanks to some big news. Which ASX All Ords stock is rocketing?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/05/01/guess-which-asx-all-ords-stock-is-rocketing-58-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["FSGS","BK7067","LU2065169927.USD","BK7508","LU2065170008.USD","DXB.AU","LU2065171402.SGD","BK4139","LU2065171311.SGD","FOLD","BK7501"],"gpt_icon":0},{"id":"2532014900","title":"Dimerix Enters License Agreement to Commercialize DMX-200 Drug Candidate in the US, Shares Surge 43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2532014900","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532014900?lang=en_us&edition=fundamental","pubTime":"2025-05-01 09:02","pubTimestamp":1746061329,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) and Amicus Therapeutics entered into an exclusive license agreement for the commercialization of Dimerix's drug candidate DMX-200 in the US, according to a Thursday Australian bourse","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DMX","BK7501","FSGS","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2532501587","title":"BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532501587","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532501587?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:15","pubTimestamp":1746054919,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix And Amicus Therapeutics Announce Exclusive License Agreement For DMX-200 In United StatesMay 1  - Dimerix Ltd DXB.AX:DIMERIX AND AMICUS THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR DMX-200 IN UNITED STATESDIMERIX TO RECEIVE US$30 MILLION UPFRONT PAYMENTDIMERIX TO RECEIVE UP TO US$560 MILLION FOR SUCCESS-BASED MILESTONE PAYMENTSFurther company coverage: DXB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BK7508","LU2065170008.USD","FOLD","BK7067","DXB.AU","BK4139","LU2065169927.USD","BK7501","LU2065171311.SGD"],"gpt_icon":0},{"id":"2532601534","title":"Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532601534","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532601534?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:12","pubTimestamp":1746054720,"startTime":"0","endTime":"0","summary":"Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis . DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and fatal kidney disease with no FDA-approved therapies. Dimerix successfully completed Type C meeting with the FDA in March 2025, aligning on proteinuria as the primary endpoint for approval. Dimerix to receive US$30 million  upfront payment, up to US$560 million  for success-based milestone payments, in addition to tiered royalties on DMX-200 net U.S. sales. “We are delighted to partner with Amicus in the United States. The Amicus team has a remarkable history of successfully delivering rare disease medicines to those in need. Their expertise and resources will be crucial to help achieve our mutual objective of commercializing this innovative treatment,” said Dr. Nina Webster, CEO and Managing Director of Dimerix. “I’m grateful to the dedicated Dimerix team, trial participants, and investigators for their contin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/dimerix-amicus-therapeutics-announce-exclusive-231200447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["UBCP","DXBO.AU","LU2065171311.SGD","LU2065169927.USD","BK4211","DMX","LU2065171402.SGD","FOLD","BK4139","ARB","FSGS","LU2065170008.USD","DXB.AU"],"gpt_icon":0},{"id":"2532130930","title":"Dimerix Ltd -  Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for Dmx-200 in United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2532130930","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532130930?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:10","pubTimestamp":1746054655,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7067","DXB.AU"],"gpt_icon":0},{"id":"2532015821","title":"Dimerix Ltd -  Dimerix to Receive US$30 Mln Upfront Payment","url":"https://stock-news.laohu8.com/highlight/detail?id=2532015821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532015821?lang=en_us&edition=fundamental","pubTime":"2025-05-01 07:10","pubTimestamp":1746054655,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R8371:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7067","BK7501","BK7508"],"gpt_icon":0},{"id":"2531319216","title":"BRIEF-Dimerix Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2531319216","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531319216?lang=en_us&edition=fundamental","pubTime":"2025-04-29 09:44","pubTimestamp":1745891050,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Seeks Trading HaltApril 29 (Reuters) - Dimerix Ltd DXB.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT ON LICENSING AGREEMENTFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2531298476","title":"Dimerix - Seeks Trading Halt Pending Announcement on Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2531298476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531298476?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:32","pubTimestamp":1745879522,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nFWN3R62K9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2516136766","title":"Dimerix Receives AU$3.2 Million Upfront Payment from FUSO Pharmaceutical Under DMX-200 License Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2516136766","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516136766?lang=en_us&edition=fundamental","pubTime":"2025-03-04 11:32","pubTimestamp":1741059169,"startTime":"0","endTime":"0","summary":"Dimerix  received an upfront payment of roughly AU$3.2 million from FUSO Pharmaceutical Industries in relation to a license agreement for hypertension and kidney disease drug candidate DMX 200, according to a Tuesday filing with the Australian bourse.Under the agreement, FUSO has the exclusive rights to commercialize DMX 200 for Focal Segmental Glomerulosclerosis kidney disease in Japan. Dimerix retains all rights to commercialize DMX-200 in all territories other than those covered by FUSO, and two other licensees, namely Advanz Pharma and Taiba, per the filing.The Australian biopharmaceutical company is entitled to receive further payments once it reaches certain development milestones.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DXB.AU","BK7067","XKO.AU","DMX","XJO.AU","XAO.AU","BK7501"],"gpt_icon":0},{"id":"2516269987","title":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSO","url":"https://stock-news.laohu8.com/highlight/detail?id=2516269987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516269987?lang=en_us&edition=fundamental","pubTime":"2025-03-04 09:23","pubTimestamp":1741051414,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Receives Initial Upfront Payment From FUSOMarch 4  - Dimerix Ltd DXB.AX:RECEIVED UPFRONT PAYMENT OF 300 MILLION FROM FUSO PHARMACEUTICAL INDUSTRIESDIMERIX RECEIVES INITIAL UPFRONT PAYMENT FROM FUSOANTICIPATES A FURTHER 400 MILLION FROM FUSOFurther company coverage: DXB.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","DXB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2516692168","title":"Dimerix posts modest gain as first Japanese payment for DMX-200 lands","url":"https://stock-news.laohu8.com/highlight/detail?id=2516692168","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516692168?lang=en_us&edition=fundamental","pubTime":"2025-03-04 07:46","pubTimestamp":1741045560,"startTime":"0","endTime":"0","summary":"Dimerix Ltd  has confirmed its receipt of its first $3.2 million payment from Japan’s FUSO Pharmaceutical Industries as part of a deal struck in January.Under that deal, FUSO and Dimerix teamed up to develop and commercialise Dimerix’s drug ‘DMX-200’ in Japan, which treats Focal Segmental Glomerulosclerosis , a scar tissue disease affecting kidneys.The $3.2M upfront payment is the first of multiple Dimerix expects, with up to $30M in payments possible under the FUSO deal. Another $4.1M is expected in the next six to 12 weeks as the first clinical trial in Japan begins.That timeframe is based on the certainty FUSO is already identifying trial sites ahead of the ‘ACTION3’ trial. Notably, FUSO is also responsible for all trial costs.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/dimerix-posts-modest-gain-as-first-japanese-payment-for-dmx-200-lands-2025-03-04/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["DMX","BK7508","FSGS","DXB.AU","BK7501","BK7067"],"gpt_icon":0},{"id":"2516666705","title":"Dimerix Ltd - Dimerix Receives Initial Upfront Payment From Fuso","url":"https://stock-news.laohu8.com/highlight/detail?id=2516666705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516666705?lang=en_us&edition=fundamental","pubTime":"2025-03-04 05:33","pubTimestamp":1741037617,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0YV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2514803966","title":"BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803966","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514803966?lang=en_us&edition=fundamental","pubTime":"2025-02-25 12:36","pubTimestamp":1740458171,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Logs Loss For Half-Year Attributable A$12.9 MlnFeb 25 (Reuters) - Dimerix Ltd DXB.AX:LOSS FOR HALF-YEAR ATTRIBUTABLE A$12.9 MILLIONFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nFWN3PF23H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2514704820","title":"Dimerix Ltd -  Loss for Half-Year Attributable a$12.9 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514704820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514704820?lang=en_us&edition=fundamental","pubTime":"2025-02-25 06:08","pubTimestamp":1740434926,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250224:nFWN3PF23H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7501","BK7508","BK7067"],"gpt_icon":0},{"id":"2510721814","title":"Lowering Dimerix's Phase 3 Trial Hurdles to Boost Kidney Failure Treatment Drug Appeal, Euroz Hartleys Says.","url":"https://stock-news.laohu8.com/highlight/detail?id=2510721814","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510721814?lang=en_us&edition=fundamental","pubTime":"2025-02-11 07:40","pubTimestamp":1739230827,"startTime":"0","endTime":"0","summary":"Lowering the approval hurdles in Dimerix's (ASX:DXB) Phase 3 trial is expected to boost the success, value, and appeal of the company's kidney failure therapy, DMX-200, to potential US partners, accor","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","BK7508","DXB.AU","BK7067"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[]}}